Gibson Dunn Advises Shareholders on Sale of Aicuris to Asahi Kasei

Gibson Dunn represented the shareholders in the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, executed through Asahi Kasei’s subsidiary Veloxis Pharmaceuticals, Inc. The transaction comprised the acquisition of Aicuris Anti-infective Cures AG by Asahi Kasei. The agreed purchase price amounts to €780 million (approximately $920 million USD). Gibson Dunn represented the shareholders with a team composed by: partners Dr. Dirk Oberbracht and Sonja Ruttmann (M&A, team co-leads); partner Ryan Murr (M&A); of counsel Dr. Aliresa Fatemi (M&A); and associates Simon Stöhlker, Andreas Rief, Tim Windfelder, and David Lübkemeier (M&A). Partners Dr. Lars Petersen and Kai Gesing and associate Yannick Oberacker advised on regulatory and antitrust matters. Partners Benjamin Rapp and Sean Feller and associates Daniel Reich and Nicolas von Wallis advised on tax matters. Of counsel Dr. Peter Gumnior advised on labor law aspects.

Menu

Gibson Dunn Advises Shareholders on Sale of Aicuris to Asahi Kasei

Read the full story

Menu

Gibson Dunn Advises Shareholders on Sale of Aicuris to Asahi Kasei

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads